Arima's 3D Genome Map: A World-Changing Idea Rewriting Cancer Care

CARLSBAD, CA – June 16, 2026 – In the relentless battle against cancer, progress is often measured in incremental steps. But occasionally, a leap occurs that fundamentally alters the landscape. Arima Genomics, a diagnostics firm based in Carlsbad, is making such a leap. The company's Aventa™ Lymphoma test was recently named an honoree in Fast Company’s 2026 World Changing Ideas Awards, a recognition that places it alongside innovations aiming to solve society’s most urgent challenges. While awards can sometimes be mere marketing accolades, this one signals a deeper shift in how we diagnose and, ultimately, treat complex cancers.

For decades, the tools used to find cancer-driving genetic mutations have been akin to reading a book one page at a time, hoping to find a typo. Arima’s approach is more like understanding the book’s entire three-dimensional structure—how distant pages fold and touch to create new meaning. This structural view is uncovering critical information that older methods miss, with profound implications for patients, clinicians, and the business of precision oncology. As Fast Company editor-in-chief Brendan Vaughan noted, the awards are “a measure of real-world impact,” and the impact here is a move toward truly personalized cancer care, driven by a more complete genomic picture.

Decoding Cancer's 3D Blueprint

The technological engine behind the Aventa Lymphoma test is a proprietary application of Hi-C sequencing. Traditional sequencing methods read DNA as a linear, one-dimensional code. The conventional method for detecting large-scale genetic rearrangements in lymphoma, known as FISH (fluorescent in situ hybridization), is more targeted but still limited. It requires pathologists to know what they are looking for, using specific molecular “probes” to hunt for suspected abnormalities one by one. This process is time-consuming, consumes precious biopsy tissue, and, most critically, can miss anything unexpected.

Arima’s Hi-C technology transcends these limitations by capturing the genome’s three-dimensional architecture. Within a cell's nucleus, DNA is folded into a complex structure, bringing genes that are linearly distant into close physical proximity. In cancer cells, this structure is often hijacked; chromosomes break and reattach incorrectly, creating gene fusions and rearrangements that can drive tumor growth. Hi-C technology creates a genome-wide map of these long-range DNA interactions. It offers a single, unbiased view that can uncover any rearrangement, regardless of whether it was previously known or suspected.

This is the difference between having a street address and having a complete satellite map of the entire city. Research has validated this advantage. In one study of 159 lymphoma cases, Hi-C sequencing successfully detected 97% of clinically important biomarkers, compared to just 76% for FISH. More importantly, it identified additional, often actionable, biomarkers in over a quarter of cases that were missed entirely by the conventional method. This isn't just an incremental improvement; it's a fundamental change in diagnostic power.

From Lab Bench to Bedside: Redefining Patient Outcomes

The business of healthcare innovation is ultimately judged by its effect on human lives. On this front, the clinical evidence for Aventa Lymphoma is compelling. The ability to see the full picture of genomic rearrangements is directly altering treatment pathways and providing clarity where there was once ambiguity. In one documented case, a patient with an aggressive lymphoma had a negative FISH test for a key rearrangement. The Aventa test, however, detected a cryptic version of the exact same event, prompting the oncologist to add a preventative therapy to guard against the cancer spreading to the central nervous system—a decision that could prove life-altering.

In another instance, a patient with an atypical lymphoid disorder was facing a difficult diagnosis. Arima’s test uncovered an unexpected gene fusion that pointed toward a different, more specific type of leukemia. This finding allowed clinicians to reconsider the diagnosis and explore more appropriate treatment strategies. The test has even enabled physicians to de-escalate therapy. One patient with an abnormal growth avoided aggressive chemotherapy after Aventa identified a specific rearrangement that confirmed a less aggressive diagnosis, allowing for a milder treatment that led to complete remission.

“This technology enhances diagnostic precision, subtype classification, prognostic evaluation, and tailored treatment strategies,” explained the director of the cancer cytogenetics laboratory at a leading university hospital. The test’s ability to work with routine FFPE samples—the preserved, paraffin-embedded tissues that are standard in pathology labs—makes it highly practical for clinical adoption. By providing comprehensive results from a single assay, it streamlines the diagnostic workflow, conserves irreplaceable patient tissue, and reduces the diagnostic odyssey for complex cases.

A Structural Shift in the Oncology Market

With its Fast Company honor and a “Clinical Diagnostics Solution of the Year” award from Biotech Breakthrough, Arima Genomics is signaling its ambition to disrupt the multi-billion-dollar cancer diagnostics market. Led by CEO Tom Willis, a veteran of the genomics industry, the company is positioning its 3D genomics platform not as a niche tool, but as a foundational technology for the future of precision medicine. The company’s vision extends well beyond lymphoma.

An equivalent test for solid tumors, Aventa FusionPlus, is already demonstrating the platform's versatility. It has successfully identified actionable gene fusions in sarcomas, brain tumors, and other cancers, often after other advanced sequencing methods failed. In a pediatric brain tumor case, the technology detected a complex rearrangement involving the PD-L1 gene, a critical biomarker for immunotherapy, opening up a treatment avenue that was previously invisible. This ability to find answers in the most challenging cases is Arima’s core value proposition.

“We are honored to be named to Fast Company’s World Changing Ideas list and consider it a testament to the innovative efforts of our entire team,” said Dr. Willis. That effort is focused on a clear market need: an estimated half of all cancer patients are not treated based on their tumor’s molecular profile, often because current tests can’t find an actionable driver. By revealing the hidden structural architecture of the cancer genome, Arima Genomics is building a powerful new lens to find those missing drivers and deliver on the long-held promise of precision oncology.